CATL begins construction of EV battery plant in Indonesia
The initial stage of construction is scheduled to be completed by the end of 2026, with a production capacity of around 7 gigawatt hours (GWh) of lithium-ion batteries per year for domestic and overseas EV manufacturers. Production capacity will be more than doubled to 15 GWh per year by the end of the decade, according to Energy Ministry spokesperson Dwi Anggia.
The battery plant is part of a broader integrated EV battery manufacturing and supply chain project valued at US$ 6 billion in total, originally signed in 2022. This includes the establishment of battery minerals mining and smelting operations in East Halmahera, North Maluku Province, by the ANTAM-IBC-CBL Consortium led by state-owned mining company PT Aneka Tambang Tbk (ANTAM), as well as the establishment of battery mineral processing operations, including high-pressure acid leach (HPAL) processing, for the production of battery precursors and cathodes.
North Maluku is rich in mineral resources such as nickel, cobalt and copper. A pyrometallurgical smelter is scheduled to begin operations by early 2027, with an annual capacity of 88,000 tons of refined nickel per year, while a hydrometallurgical smelter will have a production capacity of 55,000 tons of mixed hydroxide precipitate annually by 2028. A facility will also be built to produce Nickel Cobalt Manganese (NCM) cathode materials with a capacity of 30,000 tons per year from 2028.
The government has set a target for Indonesia to produce around 600,000 battery electric vehicles (BEVs) per year by 2030. The plant will also produce batteries for energy storage systems (ESS).
"CATL begins construction of EV battery plant in Indonesia" was originally created and published by Just Auto, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Graco Inc. (GGG): A Bull Case Theory
We came across a bullish thesis on Graco Inc. on FluentinQualitys Substack. In this article, we will summarize the bulls' thesis on GGG. Graco Inc.'s share was trading at $83.98 as of July 31st. GGG's trailing and forward P/E were 29.78 and 28.41, respectively according to Yahoo Finance. A technician in a factory controlling the production of fluid and powder materials. Graco is a quiet yet dominant leader in the fluid handling industry, engineering precision equipment that moves, measures, and controls fluids across a wide range of applications. Its narrow focus on specialized segments—such as paint spraying, lubrication systems, industrial pumps, and process equipment—has allowed it to deeply entrench itself across diverse industries, including automotive, construction, food processing, energy, and manufacturing. Graco's systems are not mere tools; once integrated into production lines, they become indispensable infrastructure. This stickiness results from high reliability, material-specific design, and a customer-centric service model that minimizes downtime. Customers rarely switch, and the installed base grows over time, supporting a recurring revenue stream through aftermarket parts, servicing, and system upgrades. Growth is driven both organically—through innovation and geographic expansion—and through bolt-on acquisitions that deepen Graco's niche dominance. Each sale opens the door to long-term value, with cross-selling opportunities across sectors and regions. The company operates globally, yet succeeds locally by maintaining close customer proximity via strong distribution, on-site support, and deep relationships with equipment integrators. Financially, Graco demonstrates impressive discipline: strong gross margins, low capital needs, high free cash flow, and minimal debt. It avoids financial engineering, compounding steadily through operational execution. Long-term industrial trends—including automation, environmental regulation, and demand for efficiency—serve as secular tailwinds, reinforcing Graco's relevance. As industries modernize, Graco's embedded solutions often remain for decades. Unlike companies chasing rapid cycles, Graco builds for endurance—with products that last, customers that stay, and revenue that expands quietly. Where others sell equipment, Graco sells precision—and becomes an integral part of the process. Previously, we covered a on Graco Inc. (GGG) by Stock Analysis Compilation in December 2024, which highlighted its premium fluid handling products, strong margins, and resilient parts business. The company's stock price has remained flat since our coverage. The thesis still stands as Graco's pricing power and durable demand persist. FluentinQuality shares a similar view but emphasizes operational embeddedness and compounding discipline. Graco Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 30 hedge fund portfolios held GGG at the end of the first quarter which was 26 in the previous quarter. While we acknowledge the potential of GGG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Drugmakers are pouring billions of dollars into new US manufacturing. It still won't achieve all of Trump's tariff goals
Ever since President Donald Trump started promising to slap tariffs on pharmaceutical imports, drugmakers have unveiled a flurry of commitments to build or expand US manufacturing operations in the coming years. AstraZeneca is investing $50 billion to expand its drug manufacturing in the US. Johnson & Johnson is pouring $55 billion into domestic production and research. And Eli Lilly said it will spend $27 billion to build four new manufacturing plants here. In total, the planned investments exceed $250 billion, according to two industry analysts. Trump is wielding the threat of tariffs to get drugmakers to increase their domestic production, which he says will strengthen national security. He's also pushing pharmaceutical companies to reduce their prices, one of his longstanding goals. But the pharma companies' moves are not expected to decrease the United States' reliance on foreign sources for key pharmaceutical ingredients and drugs, experts say. Nor are they likely to result in lower costs for American consumers. Still, the White House regularly touts the steady drumbeat of commitments as proof Trump's strategy is working. 'Another win for American manufacturing. @AstraZeneca's $50 billion pledge to expand U.S. manufacturing and R&D shows our tariff strategy at work,' Commerce Secretary Howard Lutnick posted on X in late July. 'The investment will bring high-paying jobs to Virginia, Indiana, Texas, and across the country while hardening our supply chains. Reshoring pharma production is one of our top priorities.' But it's just not that simple. Complex supply chain The pharmaceutical industry is a global web, with ingredients and finished drugs being manufactured in a multitude of locations around the world. The economics of brand name and generic drug manufacturing vary widely, and the price that the US consumer ultimately pays is determined by multiple players and factors. Both American and foreign drugmakers already produce many medications in the US and have been investing in their operations here for years. The prospect of tariffs certainly has prompted some brand-name manufacturers to shift more production to the US. However, some of the investments were already in the works before Trump took office, and other commitments may never be fulfilled, analysts say. Johnson & Johnson's $55 billion investment announcement in March, for instance, included the building of a North Carolina facility that was originally unveiled in October. 'They are just reiterating it because they're probably trying to make sure that the president is aware that they have manufacturing here and that they are listening to him,' Evan Seigerman, senior biopharma analyst at BMO Capital Markets, said of pharmaceutical companies. 'They're playing ball. It's all about the deal with President Trump.' Generic drugmakers, however, are not making the same types of commitments – largely because they can't afford to, as their profit margins are much thinner. While certain generic medicines are made in the United States, including sterile injectable drugs, oral liquid medications and controlled substances, the majority of drugs in pill or capsule form are produced abroad, primarily in India. But two generic drug manufacturers have announced domestic investments in recent months, according to the Association for Accessible Medicines, a trade group for the generic and biosimilar drug industries. Hikma Pharmaceuticals USA said it would invest $1 billion by 2030 to expand its manufacturing and research and development capabilities in several US locations, while Amphastar Pharmaceuticals said it would quadruple its production in the next three to five years. They both manufacture sterile injectable drugs, among other products. Other companies are more hesitant. 'We're not sure the market will support it if we build it,' said John Murphy III, the industry association's CEO, noting that reimbursements are so low that companies may not get returns on their investments. Much of the national security concerns center on generic drugs, which account for more than 90% of US prescriptions and are also critical to medicine administered in hospitals and doctors' offices. A sizeable share of the supply chain for certain generic medications comes from abroad and could be disrupted during geopolitical crises, a risk that's been repeatedly flagged by a bipartisan group of senators. Blanket tariffs, however, won't spur more domestic manufacturing of these drugs, said Erin Fox, associate chief pharmacy officer at the University of Utah Health. 'It's highly, highly unlikely we will see generic production expand in the US without significant incentives for these companies,' she said. 'If we do move production on some drugs to the US because we want to be sure from a national security standpoint, that's fine, but that's going to cost money.' Just what tariffs the pharmaceutical industry will face – and on which products from which countries – remain to be seen. The Trump administration is in the midst of negotiating various trade deals and has yet to release the findings of its investigation into national security implications of drug imports, which is expected to set the stage for tariffs on the industry. In late July, Trump unveiled the framework of a deal with the European Union, which calls for a 15% tariff on pharmaceutical imports – though some generic drugs could be exempt. Trump had been signaling in recent weeks that he would soon announce drug tariffs of up to 200%, but that he would give drugmakers a year or so to expand their domestic production before the full amount kicks in. That would be enough time for some companies to expand existing operations, though building new facilities could take three to five years, experts said. Even so, it's difficult for the manufacturers to make significant longer-term investment decisions amid the uncertainty of both the tariffs and future presidential administrations. Cost considerations Increasing their domestic manufacturing will help brand name drug companies escape tariffs, though they may have to pay some levies if they import pharmaceutical ingredients from other countries. Still, making more drugs in the US doesn't mean that the products will be any cheaper for patients, experts say. For one thing, the cost of production is typically higher in the US, said Stephen Farrelly, ING's global health care sector lead. Plus, the prices that consumers pay are largely governed by the nation's complex health system, which includes manufacturers, insurers and pharmacy benefit managers, known as PBMs. So whether Americans get a break on the high cost of their prescriptions will also depend on whether the president can achieve his other initiatives, including bringing US prices more in line with those in Europe and reforming the PBM industry, he said. While brand name manufacturers have more wiggle room to absorb some of the increased expenses, many experts believe they will pass along at least some of the added burden to consumers – who could eventually feel it in their out-of-pocket cost at the pharmacy counter or in their monthly insurance premiums. As for generic medicine, shifting more manufacturing to the US would entail higher production costs, which these companies could not afford to cover. Tariffs would be more likely to prompt these drugmakers to pull out of the US market, exacerbating shortages. 'At a time when the administration is clearly looking to still keep the cost down, we don't see a wholesale redistribution of generic capacity towards the US anytime soon,' Farrelly said. Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Lucid Group, Inc. (LCID) Opens Phoenix Hub, Accelerates Gravity SUV Production and Job Growth
We recently compiled a list of the 10 Best Low Cost Stocks To Buy Under $50. Lucid Group, Inc. stands tenth on our list. Lucid Group, Inc. (NASDAQ:LCID) is among the cheap stocks to buy. It is a U.S.-based luxury EV manufacturer known for its Lucid Air sedan and is expanding its footprint with the upcoming Gravity SUV and a growing emphasis on advanced technology. The company operates high-tech manufacturing facilities in Arizona and focuses on performance, efficiency, and premium features. In July 2025, Lucid Group, Inc. (NASDAQ:LCID) launched key updates to its DreamDrive Pro driver-assistance system, including new hands-free driving and automated lane change features. These enhancements, delivered via over-the-air updates, place the company among leaders in driving automation and align with its long-term push toward autonomous capabilities. The corporation also announced that Air owners will gain access to Tesla's Supercharger network starting July 31, 2025, through a NACS adapter. This dramatically improves charging accessibility for LCID drivers and addresses a core challenge for EV adoption. The business expanded its manufacturing capacity with the opening of the Phoenix Hub, acquired from Nikola Corporation. This facility will support the production of the Gravity SUV and a future midsize EV platform, and is expected to create up to 500 jobs over the next few years. On the supply chain front, Lucid Group, Inc. (NASDAQ:LCID) partnered with critical mineral producers to strengthen sourcing resilience and support sustainable vehicle production in the U.S. Looking ahead, the company is ramping up Gravity SUV production and plans a 1:10 reverse stock split aimed at attracting a broader investor base. Additionally, a new marketing campaign featuring actor Timothée Chalamet will debut in fall 2025, reinforcing the corporation's image as a premium, innovative brand. While we acknowledge the potential of LCID as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
